| Name | Title | Contact Details |
|---|
Discovering new medicines by combining ultra throughput biochemistry and machine learning.
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company that is seeking to unlock the full potential of biologic therapies by avoiding unwanted immune responses. Selecta`s tolerogenic Synthetic Vaccine Particles (SVP™) technology platform is designed to enable a range of novel biologics for rare and serious diseases that require new treatment options. The company`s current proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. SEL-212, the company`s lead candidate in Phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. Selecta`s clinical oncology candidate, LMB-100, is in a Phase 1 program targeting pancreatic cancer and mesothelioma. Its two proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat administration. The use of SVP is also being explored in the development of vaccines and treatments for allergies and autoimmune diseases. Selecta is based in Watertown, Massachusetts.
Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.
Vesigen is developing groundbreaking therapeutic products directed to intracellular targets using a scalable and extracellular vesicle delivery technology.
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.